Sorafenib suppresses TGF-ß responses by inducing caveolae/lipid raft-mediated internalization/degradation of cell-surface type II TGF-ß receptors: Implications in development of effective adjunctive therapy for hepatocellular carcinoma.
Biochem Pharmacol
; 154: 39-53, 2018 08.
Article
in En
| MEDLINE
| ID: mdl-29678520
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Transforming Growth Factor beta
/
Carcinoma, Hepatocellular
/
Caveolae
/
Membrane Microdomains
/
Sorafenib
/
Receptor, Transforming Growth Factor-beta Type II
/
Liver Neoplasms
Limits:
Animals
/
Humans
/
Male
Language:
En
Journal:
Biochem Pharmacol
Year:
2018
Document type:
Article
Country of publication:
United kingdom